Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

Ian J Neeland, Darren K McGuire, Björn Eliasson, Martin Ridderstråle, Cordula Zeller, Hans J. Woerle, Uli C. Broedl, Odd Erik Johansen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: Excess adiposity contributes to cardiometabolic disease. Although adipose depots can be measured using imaging, implementation remains limited in practice. Data comparing surrogate indices of total and visceral adiposity with gold standard measurements in the context of a clinical trial population are lacking. We explored the relationships between adipose distribution indices and imaging assessments of body composition using baseline data from the EMPA-REG H2H SU™ trial. Methods: 118 participants from the Phase III trial of empagliflozin 25 mg vs. glimepiride 1–4 mg enrolled in a dedicated sub-study underwent assessment of total fat and fat-free mass by dual x-ray absorptiometry (n = 93) and abdominal visceral (VAT) and subcutaneous adipose tissue by magnetic resonance imaging (n = 99). Correlations with waist circumference (WC), estimated total body fat (eTBF), index of central obesity (ICO), and visceral adiposity index (VAI) were assessed. Results: eTBF was highly representative of total body fat (Spearman’s ρ = 0.73, P 

Original languageEnglish (US)
Pages (from-to)635-642
Number of pages8
JournalDiabetes Therapy
Volume6
Issue number4
DOIs
StatePublished - Dec 1 2015

Fingerprint

Adiposity
Body Composition
Adipose Tissue
glimepiride
Fats
Abdominal Fat
Intra-Abdominal Fat
Abdominal Obesity
Subcutaneous Fat
Waist Circumference
Magnetic Resonance Imaging
X-Rays
Clinical Trials
Population

Keywords

  • Body fat distribution
  • Empagliflozin
  • Obesity
  • Sodium glucose co-transporter 2 inhibitor
  • Visceral adipose tissue

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial : A Body Composition Sub-Study. / Neeland, Ian J; McGuire, Darren K; Eliasson, Björn; Ridderstråle, Martin; Zeller, Cordula; Woerle, Hans J.; Broedl, Uli C.; Johansen, Odd Erik.

In: Diabetes Therapy, Vol. 6, No. 4, 01.12.2015, p. 635-642.

Research output: Contribution to journalArticle

Neeland, Ian J ; McGuire, Darren K ; Eliasson, Björn ; Ridderstråle, Martin ; Zeller, Cordula ; Woerle, Hans J. ; Broedl, Uli C. ; Johansen, Odd Erik. / Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial : A Body Composition Sub-Study. In: Diabetes Therapy. 2015 ; Vol. 6, No. 4. pp. 635-642.
@article{d9f96f54faba4339ad6c11165255a39e,
title = "Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study",
abstract = "Introduction: Excess adiposity contributes to cardiometabolic disease. Although adipose depots can be measured using imaging, implementation remains limited in practice. Data comparing surrogate indices of total and visceral adiposity with gold standard measurements in the context of a clinical trial population are lacking. We explored the relationships between adipose distribution indices and imaging assessments of body composition using baseline data from the EMPA-REG H2H SU™ trial. Methods: 118 participants from the Phase III trial of empagliflozin 25 mg vs. glimepiride 1–4 mg enrolled in a dedicated sub-study underwent assessment of total fat and fat-free mass by dual x-ray absorptiometry (n = 93) and abdominal visceral (VAT) and subcutaneous adipose tissue by magnetic resonance imaging (n = 99). Correlations with waist circumference (WC), estimated total body fat (eTBF), index of central obesity (ICO), and visceral adiposity index (VAI) were assessed. Results: eTBF was highly representative of total body fat (Spearman’s ρ = 0.73, P ",
keywords = "Body fat distribution, Empagliflozin, Obesity, Sodium glucose co-transporter 2 inhibitor, Visceral adipose tissue",
author = "Neeland, {Ian J} and McGuire, {Darren K} and Bj{\"o}rn Eliasson and Martin Ridderstr{\aa}le and Cordula Zeller and Woerle, {Hans J.} and Broedl, {Uli C.} and Johansen, {Odd Erik}",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s13300-015-0146-7",
language = "English (US)",
volume = "6",
pages = "635--642",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "4",

}

TY - JOUR

T1 - Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial

T2 - A Body Composition Sub-Study

AU - Neeland, Ian J

AU - McGuire, Darren K

AU - Eliasson, Björn

AU - Ridderstråle, Martin

AU - Zeller, Cordula

AU - Woerle, Hans J.

AU - Broedl, Uli C.

AU - Johansen, Odd Erik

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Introduction: Excess adiposity contributes to cardiometabolic disease. Although adipose depots can be measured using imaging, implementation remains limited in practice. Data comparing surrogate indices of total and visceral adiposity with gold standard measurements in the context of a clinical trial population are lacking. We explored the relationships between adipose distribution indices and imaging assessments of body composition using baseline data from the EMPA-REG H2H SU™ trial. Methods: 118 participants from the Phase III trial of empagliflozin 25 mg vs. glimepiride 1–4 mg enrolled in a dedicated sub-study underwent assessment of total fat and fat-free mass by dual x-ray absorptiometry (n = 93) and abdominal visceral (VAT) and subcutaneous adipose tissue by magnetic resonance imaging (n = 99). Correlations with waist circumference (WC), estimated total body fat (eTBF), index of central obesity (ICO), and visceral adiposity index (VAI) were assessed. Results: eTBF was highly representative of total body fat (Spearman’s ρ = 0.73, P 

AB - Introduction: Excess adiposity contributes to cardiometabolic disease. Although adipose depots can be measured using imaging, implementation remains limited in practice. Data comparing surrogate indices of total and visceral adiposity with gold standard measurements in the context of a clinical trial population are lacking. We explored the relationships between adipose distribution indices and imaging assessments of body composition using baseline data from the EMPA-REG H2H SU™ trial. Methods: 118 participants from the Phase III trial of empagliflozin 25 mg vs. glimepiride 1–4 mg enrolled in a dedicated sub-study underwent assessment of total fat and fat-free mass by dual x-ray absorptiometry (n = 93) and abdominal visceral (VAT) and subcutaneous adipose tissue by magnetic resonance imaging (n = 99). Correlations with waist circumference (WC), estimated total body fat (eTBF), index of central obesity (ICO), and visceral adiposity index (VAI) were assessed. Results: eTBF was highly representative of total body fat (Spearman’s ρ = 0.73, P 

KW - Body fat distribution

KW - Empagliflozin

KW - Obesity

KW - Sodium glucose co-transporter 2 inhibitor

KW - Visceral adipose tissue

UR - http://www.scopus.com/inward/record.url?scp=84949223572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949223572&partnerID=8YFLogxK

U2 - 10.1007/s13300-015-0146-7

DO - 10.1007/s13300-015-0146-7

M3 - Article

C2 - 26608511

AN - SCOPUS:84949223572

VL - 6

SP - 635

EP - 642

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 4

ER -